 Stephen Jensik
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 5 | 2022 | 132 | 0.780 |
Why?
| | Kidney Transplantation | 9 | 2019 | 153 | 0.770 |
Why?
| | Arteriovenous Shunt, Surgical | 4 | 2022 | 23 | 0.690 |
Why?
| | Immunosuppressive Agents | 7 | 2019 | 166 | 0.630 |
Why?
| | Catheter Obstruction | 1 | 2013 | 3 | 0.480 |
Why?
| | Angioplasty, Balloon | 1 | 2013 | 28 | 0.470 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 27 | 0.470 |
Why?
| | Catheterization, Central Venous | 1 | 2013 | 41 | 0.460 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2013 | 45 | 0.460 |
Why?
| | Stents | 1 | 2013 | 159 | 0.420 |
Why?
| | Graft Occlusion, Vascular | 3 | 2022 | 29 | 0.330 |
Why?
| | Liver Transplantation | 2 | 2014 | 112 | 0.310 |
Why?
| | Graft Survival | 6 | 2019 | 110 | 0.310 |
Why?
| | Mycophenolic Acid | 5 | 2019 | 15 | 0.310 |
Why?
| | Graft Rejection | 4 | 2019 | 87 | 0.300 |
Why?
| | Tacrolimus | 5 | 2019 | 14 | 0.300 |
Why?
| | Vascular Patency | 4 | 2022 | 31 | 0.290 |
Why?
| | Upper Extremity | 2 | 2016 | 47 | 0.270 |
Why?
| | Kidney Failure, Chronic | 2 | 2019 | 188 | 0.260 |
Why?
| | Carrier Proteins | 2 | 2016 | 126 | 0.260 |
Why?
| | Isoxazoles | 1 | 2002 | 17 | 0.220 |
Why?
| | Arteriovenous Fistula | 1 | 2022 | 12 | 0.220 |
Why?
| | Aneurysm | 1 | 2022 | 20 | 0.220 |
Why?
| | Cyclosporine | 3 | 2007 | 20 | 0.200 |
Why?
| | Surgical Instruments | 1 | 2020 | 30 | 0.200 |
Why?
| | Sirolimus | 3 | 2005 | 19 | 0.190 |
Why?
| | Treatment Outcome | 9 | 2022 | 4036 | 0.190 |
Why?
| | Health Care Costs | 1 | 2020 | 83 | 0.190 |
Why?
| | Pancreatic Elastase | 2 | 2016 | 7 | 0.190 |
Why?
| | Suture Techniques | 1 | 2020 | 149 | 0.180 |
Why?
| | Time Factors | 8 | 2022 | 1873 | 0.180 |
Why?
| | Recombinant Fusion Proteins | 2 | 2010 | 35 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 132 | 0.170 |
Why?
| | Brachial Artery | 1 | 2016 | 10 | 0.150 |
Why?
| | Radial Artery | 1 | 2016 | 17 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2022 | 3835 | 0.140 |
Why?
| | Postoperative Complications | 2 | 2020 | 1117 | 0.140 |
Why?
| | Creatinine | 5 | 2010 | 59 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 61 | 0.130 |
Why?
| | Male | 12 | 2020 | 17726 | 0.120 |
Why?
| | Female | 12 | 2020 | 18423 | 0.120 |
Why?
| | Humans | 14 | 2022 | 32988 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2014 | 113 | 0.110 |
Why?
| | Middle Aged | 10 | 2020 | 11219 | 0.100 |
Why?
| | Risk Factors | 5 | 2022 | 2762 | 0.100 |
Why?
| | Prosthesis Design | 1 | 2013 | 534 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2010 | 109 | 0.090 |
Why?
| | Adult | 9 | 2020 | 9848 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2016 | 546 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2005 | 261 | 0.080 |
Why?
| | Aged | 7 | 2020 | 10542 | 0.070 |
Why?
| | Calcineurin Inhibitors | 2 | 2005 | 11 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 293 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2005 | 22 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 216 | 0.070 |
Why?
| | Survival Analysis | 3 | 2014 | 372 | 0.060 |
Why?
| | Prospective Studies | 4 | 2016 | 2002 | 0.060 |
Why?
| | Prednisone | 1 | 2002 | 78 | 0.050 |
Why?
| | Prognosis | 2 | 2019 | 1011 | 0.050 |
Why?
| | Cost Savings | 1 | 2020 | 42 | 0.050 |
Why?
| | Anemia | 1 | 2002 | 98 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 159 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2019 | 26 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2019 | 2053 | 0.040 |
Why?
| | United States | 2 | 2016 | 2632 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 2010 | 297 | 0.030 |
Why?
| | Waiting Lists | 1 | 2014 | 18 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2014 | 6 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 43 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2014 | 289 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 494 | 0.030 |
Why?
| | Ultrasonography | 1 | 2014 | 215 | 0.030 |
Why?
| | Databases, Factual | 1 | 2014 | 393 | 0.030 |
Why?
| | Kidney | 2 | 2005 | 219 | 0.030 |
Why?
| | Reperfusion Injury | 1 | 2010 | 7 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 28 | 0.020 |
Why?
| | Tissue Donors | 1 | 2010 | 85 | 0.020 |
Why?
| | Tablets, Enteric-Coated | 1 | 2007 | 1 | 0.020 |
Why?
| | Area Under Curve | 1 | 2007 | 77 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2007 | 104 | 0.020 |
Why?
| | Postoperative Period | 1 | 2007 | 298 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2005 | 77 | 0.020 |
Why?
| | Biopsy | 1 | 2005 | 277 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 113 | 0.020 |
Why?
| | Cohort Studies | 1 | 2010 | 2077 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2003 | 26 | 0.010 |
Why?
| | Pilot Projects | 1 | 2005 | 466 | 0.010 |
Why?
| | Acute Disease | 1 | 2003 | 258 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2002 | 86 | 0.010 |
Why?
| | Hypertension | 1 | 2003 | 293 | 0.010 |
Why?
| | Incidence | 1 | 2003 | 840 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2003 | 446 | 0.010 |
Why?
|
|
Jensik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|